T1	PROC 45 83	Fase 3b, un brazo, estudio unicéntrico
T2	DISO 115 135	infectados por VIH-1
#1	AnnotatorNotes T2	C2363741; HIV-1 infection; Disease or Syndrome
T3	CHEM 183 186	3TC
#2	AnnotatorNotes T3	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T4	CHEM 204 215	Raltegravir
#3	AnnotatorNotes T4	C1871526; raltegravir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T5	CHEM 241 244	3TC
#4	AnnotatorNotes T5	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T6	CHEM 259 270	Raltegravir
#5	AnnotatorNotes T6	C1871526; raltegravir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T7	PROC 285 305	estudio de Roll-over
T8	PROC 310 325	ensayo clínicos
T9	PROC 547 558	seguimiento
#6	AnnotatorNotes T9	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T10	PROC 679 686	terapia
#7	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	CHEM 696 699	3TC
#8	AnnotatorNotes T11	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T12	CHEM 704 715	Raltegravir
#9	AnnotatorNotes T12	C1871526; raltegravir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T13	PROC 748 772	consentimiento informado
#10	AnnotatorNotes T13	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T14	DISO 917 927	enfermedad
#11	AnnotatorNotes T14	C0012634; Disease; Disease or Syndrome
T15	PROC 1069 1080	tratamiento
#12	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	DISO 1097 1125	Co-infección por hepatitis B
T17	PROC 644 655	carga viral
#13	AnnotatorNotes T17	C1261478; Viral load measurement; Laboratory Procedure
T18	DISO 945 955	enfermedad
#14	AnnotatorNotes T18	C0012634; Disease; Disease or Syndrome
T19	Date 13 17	2017
T20	LIVB 105 114	pacientes
#15	AnnotatorNotes T20	C0030705; Patients; Patient or Disabled Group
T21	Dose 188 194	150 mg
T22	Frequency 195 198	BID
T23	Dose 217 223	400 mg
T24	Frequency 224 227	BID
T25	Dose 246 252	300 mg
T26	Frequency 253 255	QD
T27	Dose 272 279	1200 mg
T28	Frequency 280 282	QD
T29	LIVB 367 376	Pacientes
#16	AnnotatorNotes T29	C0030705; Patients; Patient or Disabled Group
T30	LIVB 419 428	Pacientes
#17	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	LIVB 493 502	pacientes
#18	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group
T32	Duration 562 572	24 semanas
T34	LIVB 719 728	Pacientes
#19	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T35	PHYS 832 840	Embarazo
#20	AnnotatorNotes T35	C0032961; Pregnancy; Organism Function
T36	PHYS 842 851	lactancia
#21	AnnotatorNotes T36	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T37	PHYS 865 873	embarazo
#22	AnnotatorNotes T37	C0032961; Pregnancy; Organism Function
T38	LIVB 976 988	investigador
#23	AnnotatorNotes T38	C0035173; Research Personnel; Professional or Occupational Group
T41	LIVB 1085 1093	paciente
#24	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	LIVB 650 655	viral
#25	AnnotatorNotes T42	C0042776; Virus; Virus
T43	LIVB 130 135	VIH-1
#26	AnnotatorNotes T43	C0019704; HIV-1; Virus
A1	Status T9 History_of
A2	Status T18 History_of
#27	AnnotatorNotes T8	C0008976; Clinical Trials; Research Activity
T33	Spec_cue 990 997	pudiera
T39	Observation 998 1022	confundir los resultados
A3	Assertion T39 Speculated
T40	Observation 1049 1055	riesgo
A4	Assertion T40 Speculated
R1	Speculation Arg1:T33 Arg2:T39	
R2	Speculation Arg1:T33 Arg2:T40	
R4	Before Arg1:T18 Arg2:T39	
R5	Before Arg1:T14 Arg2:T39	
R6	Before Arg1:T14 Arg2:T40	
R7	Before Arg1:T18 Arg2:T40	
R8	Experiences Arg1:T41 Arg2:T15	
R9	Experiences Arg1:T41 Arg2:T40	
R10	Experiences Arg1:T41 Arg2:T18	
R11	Experiences Arg1:T41 Arg2:T14	
T44	Observation 140 160	supresión virológica
#28	AnnotatorNotes T44	C3888663; Sustained viral response; Finding (?)
T45	Observation 617 642	virológicamente suprimido
#29	AnnotatorNotes T45	C3888663; Sustained viral response; Finding (?)
R3	Experiences Arg1:T31 Arg2:T45	
T46	Observation 533 558	completado el seguimiento
R12	Before Arg1:T46 Arg2:T45	
R13	Has_Duration_or_Interval Arg1:T9 Arg2:T32	
R15	Experiences Arg1:T20 Arg2:T2	
R16	Causes Arg1:T43 Arg2:T2	
R17	Experiences Arg1:T20 Arg2:T44	
R18	Overlap Arg1:T2 Arg2:T44	
R19	Has_Dose_or_Strength Arg1:T3 Arg2:T21	
R20	Has_Frequency Arg1:T3 Arg2:T22	
R21	Combined_with Arg1:T3 Arg2:T4	
R22	Has_Dose_or_Strength Arg1:T4 Arg2:T23	
R23	Has_Frequency Arg1:T4 Arg2:T24	
R24	Experiences Arg1:T20 Arg2:T3	
R25	Experiences Arg1:T20 Arg2:T5	
R26	Combined_with Arg1:T5 Arg2:T6	
R27	Before Arg1:T21 Arg2:T25	
R28	Before Arg1:T23 Arg2:T27	
R29	Has_Frequency Arg1:T6 Arg2:T28	
R30	Has_Dose_or_Strength Arg1:T6 Arg2:T27	
R31	Has_Dose_or_Strength Arg1:T5 Arg2:T25	
R32	Has_Frequency Arg1:T5 Arg2:T26	
T47	Result_or_Value 656 671	<50 copias / mL
R33	Has_Result_or_Value Arg1:T17 Arg2:T47	
R34	Experiences Arg1:T31 Arg2:T17	
R35	Experiences Arg1:T31 Arg2:T10	
R36	Used_for Arg1:T11 Arg2:T10	
R37	Combined_with Arg1:T11 Arg2:T12	
T48	Quantifier_or_Qualifier 687 691	dual
#30	AnnotatorNotes T48	C1554184; Dual; Intellectual Product
R38	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T48	
R39	Overlap Arg1:T45 Arg2:T10	
T49	Observation 778 802	participar en el estudio
#31	AnnotatorNotes T49	C1278516; Patient participation status; Finding
R40	Before Arg1:T13 Arg2:T49	
T50	Observation 854 873	planificar embarazo
#32	AnnotatorNotes T50	C0032992; Pregnancy, Planned; Finding
R42	Before Arg1:T50 Arg2:T37	
T51	PROC 896 903	estudio
#33	AnnotatorNotes T51	C0008976; Clinical Trials; Research Activity
R43	Overlap Arg1:T50 Arg2:T51	
R44	Overlap Arg1:T36 Arg2:T51	
R45	Overlap Arg1:T35 Arg2:T51	
R47	Overlap Arg1:T17 Arg2:T10	
R48	Overlap Arg1:T40 Arg2:T15	
#34	AnnotatorNotes T40	C0559571; At risk; Finding
#35	AnnotatorNotes T46	C5554829; Follow-Up Completed; Finding
A5	Experiencer T31 Patient
A6	Experiencer T34 Patient
A7	Experiencer T20 Patient
A8	Experiencer T29 Patient
A9	Experiencer T30 Patient
A10	Status T37 Future
A11	Experiencer T38 Other
A12	Experiencer T41 Patient
